Statement showing the Financial Results (Standalone and Consolidated)
As filed · General Updates
EarningsNotablemateriality 73 out of 100
What happened
FactStatement showing the Financial Results (Standalone and Consolidated). Statement of Assets and Liabilities (Standalone and Consolidated). Cash Flow Statement (Standalone and Consolidated).
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ2 FY26
AarƟ Drugs posted revenue of Rs. 652.9 crore in Q2 FY26, growing 9% year-on-year, with EBITDA of Rs. 84.4 crore, up 23%, with margin at 12.9%.
NowQ2 FY26
For H1 FY26, revenue was Rs. 1,243.7 crore, up 8% year-on-year, with EBITDA of Rs. 158.8 crore, up 18% with margin at 12.8%.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 90.49%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We expect to make further progress on utilization ramp-up during FY 2027. (management committed by FY27)
- For FY '26, we feel around INR10 crores to INR15 crores might -- of benefit might come in this year itself. (management committed by FY26)
Evidence
- Aarti Drugs Limited has informed the Exchange about General Updates - Re-appointment of Cost Auditor and Internal Auditor(opens the original filing in a new tab)
- Earlier statement · Q2 FY26
- Latest statement · Q2 FY26
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%